tb morbidity
play

TB Morbidity New Jersey, 20082017 450 400 422 405 405 350 300 - PowerPoint PPT Presentation

Jan 12, 2024 •45 likes •175 views

TB Morbidity New Jersey, 20082017 450 400 422 405 405 350 300 331 319 326 307 302 294 250 282 200 150 100 50 0 TB Morbidity by Race/Ethni city New Jersey, 20082017 200 150 100 50 Asian Black Hispanic White 0

  1. TB Morbidity New Jersey, 2008–2017 450 400 422 405 405 350 300 331 319 326 307 302 294 250 282 200 150 100 50 0

  2. TB Morbidity by Race/Ethni city New Jersey, 2008–2017 200 150 100 50 Asian Black Hispanic White 0 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Asian 168 143 154 112 145 121 137 146 125 144 Black 77 89 86 71 47 55 43 48 49 42 Hispanic 128 126 123 105 79 109 103 105 98 70 White 49 44 41 43 31 34 24 27 22 26

  3. TB Morbidity by Country of Birth New Jersey, 2008–2017 450 400 350 325 310 302 300 TB Cases 302 250 249 253 253 200 251 251 236 150 100 50 102 97 95 82 66 60 60 56 49 46 0 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 US Born Foreign-Born

  4. TB Morbidity by Country of Birth New Jersey, 2017 (N=282) 16% 84% Foreign-born US Born

  5. TB Morbidity Cases/Case Rates* by County New Jersey, 2008–2017 County 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Atlantic 19/7.0 14/5.2 12/4.4 8/2.9 9/3.3 10/3.6 9/3.2 13/4.7 5/1.8 6/2.2 Bergen 44/4.9 37/4.0 43/4.8 29/3.2 38/4.2 37/3.9 29/3.1 35/3.7 30/3.2 13/1.4 Burlington 5/1.1 7/1.6 15/3.3 10/2.2 12/2.7 7/1.6 4/0.9 11/2.4 4/0.9 8/1.8 Camden 19/3.7 15/2.9 10/1.9 12/2.3 10/2.0 15/2.9 11/2.1 11/2.2 12/2.3 11/2.2 Cape May 2/2.0 1/1.0 2/2.1 3/3.1 2/2.1 2/2.1 0/0.0 2/2.1 1/1.1 1/1.1 Cumberland 4/2.6 8/5.1 6/3.8 5/3.2 5/3.2 7/4.4 4/2.5 10/6.4 8/5.1 9/5.9 Essex 71/9.1 59/7.7 54/6.9 47/6.0 40/5.1 52/6.7 33/4.2 39/4.9 41/5.1 35/4.4 Gloucester 4/1.4 5/1.7 7/2.4 4/2.4 0/0.0 1/0.6 3/1.0 3/1.0 5/1.7 4/1.4 Hudson 54/9.0 69/11.5 51/8.0 44/6.9 38/5.9 59/9.0 52/7.9 51/7.6 48/7.1 50/7.4 Hunterdon 2/1.5 2/1.5 2/1.6 2/1.6 0/0.0 1/1.0 0/0.0 4/3.2 0/0.0 4/3.2 Mercer 11/3.0 16/4.4 16/4.4 13/3.5 9/2.5 12/3.3 13/3.5 20/5.4 15/4.0 13/3.5 Middlesex 60/7.6 52/6.6 65/8.0 48/5.9 59/7.2 31/3.8 57/6.9 53/6.3 44/5.2 48/5.7 Monmouth 21/3.3 14/2.2 15/2.4 11/1.7 6/0.9 12/2.0 8/1.3 9/1.4 11/1.7 9/1.4 Morris 14/2.9 11/2.3 7/1.4 15/3.0 9/1.8 12/2.4 8/1.6 9/1.8 8/1.6 11/2.2 Ocean 6/1.1 9/1.6 17/2.9 15/2.6 7/1.2 8/1.4 18/3.1 9/1.5 9/1.5 10/1.7 Passaic 29/5.9 28/5.7 32/6.4 24/4.8 20/4.0 25/5.2 21/4.2 11/2.2 18/3.5 19/3.7 Salem 1/1.5 3/4.5 2/3.0 0/0 1/1.5 0/0 1/1.5 2/3.1 0/0.0 0/0.0 Somerset 16/4.9 17/5.2 14/4.3 9/2.8 13/4.0 6/1.8 15/4.5 9/2.7 6/1.8 10/3.0 Sussex 1/1.0 2/1.3 1/0.7 1/0.7 2/1.3 3/2.0 0/0.0 0/0.0 1/0.7 0/0.0 Union 39/7.4 33/6.3 34/6.3 31/5.8 21/4.0 18/3.3 20/3.8 24/4.4 26/4.7 19/3.4 Warren 0/0.0 3/2.7 0/0.0 0/0.0 1/0.9 1/1.0 1/0.9 1/0.9 2/1.9 2/1.9 State Total 422/4.9 405/4.7 405/4.6 331/3.8 302/3.4 319/3.6 307/3.5 326/3.7 294/3.3 282/3.2 *Cases per 100,000 population Data Source: US Census Bureau Population estimates, July 1, 2017

  6. SUSSEX Passaic PASSAIC Counted TB Cases BERGEN WARREN MORRIS New Jersey, 2013–2017 ESSEX HUDSON UNION UNION SOMERSET SOMERSET HUNTERDON ≥ 200 MIDDLESEX 100 ‒ 199 50 ‒ 99 MONMOUTH MONMOUTH MERCER 20 ‒ 49 < 20 OCEAN OCEAN BURLINGTON BURLINGTON CAMDEN GLOUCESTER SALEM ATLANTIC CUMBERLAND CAPE CAPE MAY MAY

  7. TB Morbidity and Case Rates* Select Cities New Jersey, 2008–2017 City 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Edison 11/11.0 10/10.0 15/15.0 11/11.0 16/15.9 8/7.9 10/9.8 11/10.8 7/6.8 10/9.8 Elizabeth 16/12.8 8/6.4 12/9.6 14/11.2 8/6.4 11/8.7 10/7.8 12/9.3 11/8.5 12/9.3 Jersey City 39/16.0 43/17.7 33/13.3 21/8.5 28/11.2 34/13.4 34/13.0 29/11.1 31/11.3 32/3.5 Newark 36/12.9 27/9.7 25/9.0 20/7.2 20/7.2 28/10.1 14/5.0 19/6.8 20/7.0 10/3.5 Paterson 15/10.2 15/10.3 12/8.2 12/8.2 12/8.2 5/3.4 12/8.2 6/4.1 1/0.7 12/8.2 *Cases per 100,000 population Data Source: US Census Bureau Population estimates, July 1, 2017

  8. TB Morbidity by Age Group New Jersey, 2008–2017 0–4 5–14 15–24 25–44 45–64 ≥ 65 200 150 100 50 0 Age 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 0–4 2 9 15 7 1 9 7 8 6 9 5–14 7 5 12 7 4 4 6 2 5 8 15–24 42 57 44 35 24 27 35 32 30 26 25–44 176 168 139 124 124 108 126 109 91 90 45–64 122 97 111 86 86 100 81 87 88 90 ≥ 65 73 69 84 72 64 71 52 88 74 59

  9. TB Morbidity in Health Care Workers New Jersey, 2008–2017 25 20 28 20 20 18 18 15 16 16 10 12 5 8 7 0 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

  10. TB Morbidity in Health Care Workers New Jersey, 2008–2017 450 5.2% 4.4% 4.9% 400 350 4.8% 6.5% 2.1% 5.3% 5.6% 4.1% 300 2.8% TB Cases 250 200 150 100 50 0 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 All Other HC Workers

  11. TB/HIV Co-infection New Jersey, 2008–2017 35 33 30 25 27 26 25 20 23 15 16 17 15 15 10 14 5 0 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

  12. TB/HIV Co-infection New Jersey, 2008–2017 450 7.8% 7.2% 7.2% 400 350 7.3% 5.6% 7.5% 4.9% 4.6% 5.1% 300 5.3% TB Cases 250 200 150 100 50 0 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 All other HIV Co-infection

  13. Multi-Drug Resistant TB by County New Jersey, 2008–2017 County 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Atlantic 0 0 0 0 0 0 0 0 0 0 Bergen 1 2 1 0 1 1 1 0 0 0 Burlington 0 0 0 0 0 0 0 0 0 0 Camden 0 0 0 0 0 0 0 0 0 0 Cape May 0 0 0 0 0 0 0 0 0 0 Cumberland 0 0 0 0 0 0 0 0 0 0 Essex 3 0 4 1 1 0 0 1 0 0 Gloucester 0 0 0 0 0 0 0 0 0 0 Hudson 3 2 0 3 0 2 1 2 1 0 Hunterdon 0 0 0 0 0 0 0 0 0 0 Mercer 0 0 0 1 0 0 0 0 0 0 Middlesex 0 0 3 3 1 2 1 0 0 2 Monmouth 0 0 0 0 0 0 0 0 0 0 Morris 1 0 0 0 0 0 0 0 0 0 Ocean 0 0 0 0 0 0 1 0 1 1 Passaic 0 3 0 0 1 2 0 0 1 0 Salem 0 0 0 0 0 0 0 0 0 0 Somerset 0 1 0 0 0 0 0 0 0 0 Sussex 0 0 0 0 0 0 0 1 0 0 Union 0 1 0 0 0 0 0 0 0 0 Warren 0 0 0 0 0 0 0 0 0 0 State Total 8 9 8 8 4 5 4 4 3 3

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend

WITH CRONIC MORBIDITY - THE EFFECT OF INCOME: A COMPARATIVE STUDY OF CERTAIN CAUSES OF MORBIDITY

WITH CRONIC MORBIDITY - THE EFFECT OF INCOME: A COMPARATIVE STUDY OF CERTAIN CAUSES OF MORBIDITY

WITH CRONIC MORBIDITY - THE EFFECT OF INCOME: A COMPARATIVE STUDY OF CERTAIN CAUSES OF MORBIDITY IN BRAZIL AND THE US Kaiz Iwakami Beltro Sonoe Sugahara EBAPE/FGV, kaizo.beltrao@fgv.br ENCE/IBGE, sonoe.pinheiro@ibge.gov.br

898 views • 69 slides
Fu Hua Fu Hua Fudan University Fudan University 1 Morbidity and mortality of major cancers

Fu Hua Fu Hua Fudan University Fudan University 1 Morbidity and mortality of major cancers

Cancer Impact to Population Health and Responses in China Fu Hua Fu Hua Fudan University Fudan University 1 Morbidity and mortality of major cancers increase over the years (1998-2008) 1/100 000 Morbidity, Male Morbidity, Female

176 views • 17 slides
Factors Factors of of Neonatal Neonatal Morbidity Morbidity at at the the Provincial

Factors Factors of of Neonatal Neonatal Morbidity Morbidity at at the the Provincial

Factors Factors of of Neonatal Neonatal Morbidity Morbidity at at the the Provincial Provincial Hospital Hospital Center of Center of Missour Missour Authors: Doukkali Loubna, MD, PhDs1 ; Bennani Mechita Nada2 ; Lahlou Laila2 ; Laamiri

195 views • 6 slides
TB Morbidity New Jersey, 2008 2017 450 400 422 405 405 350 300 331 319 326 307 302

TB Morbidity New Jersey, 2008 2017 450 400 422 405 405 350 300 331 319 326 307 302

TB Morbidity New Jersey, 2008 2017 450 400 422 405 405 350 300 331 319 326 307 302 294 250 283 200 150 100 50 0 TB Morbidity by Race/Ethni city New Jersey, 2008 2017 200 150 100 50 Asian Black Hispanic White 0

425 views • 13 slides
TB Morbidity New Jersey, 2009 2018 450 400 405 405 350 300 331 326 302 307 302 291

TB Morbidity New Jersey, 2009 2018 450 400 405 405 350 300 331 326 302 307 302 291

TB Morbidity New Jersey, 2009 2018 450 400 405 405 350 300 331 326 302 307 302 291 294 250 283 200 150 100 50 0 TB Morbidity by Race/Ethni city New Jersey, 2009 2018 200 150 100 50 Asian Black Hispanic White 0

553 views • 13 slides
Registered morbidity and trend Registered morbidity and trend of infections diseases in of

Registered morbidity and trend Registered morbidity and trend of infections diseases in of

Registered morbidity and trend Registered morbidity and trend of infections diseases in of infections diseases in Mongolia Mongolia I. Respiratory infections Pertussis Diphtheria Rubella Erithema infectiosa

232 views • 21 slides
Maternal Morbidity: Neglected Dimension of Safe Motherhood Karen Hardee Jill Gay Ann Blan c

Maternal Morbidity: Neglected Dimension of Safe Motherhood Karen Hardee Jill Gay Ann Blan c

Maternal Morbidity: Neglected Dimension of Safe Motherhood Karen Hardee Jill Gay Ann Blan c Silent Suffering: Maternal Morbidities in Developing Countries Woodrow Wilson Center September 27, 2011 Outline Why Focus on Maternal Morbidity?

542 views • 32 slides
and Morbidity: The Role of Drug Overdoses Presentation to the House Select Committee on Opioids

and Morbidity: The Role of Drug Overdoses Presentation to the House Select Committee on Opioids

Maternal Mortality and Morbidity: The Role of Drug Overdoses Presentation to the House Select Committee on Opioids &amp; Substance Abuse Lisa Hollier, M.D., M.P.H Chair, Maternal Mortality and Morbidity Task Force Manda Hall, M.D. Associate

486 views • 23 slides
and Maternal Mortality Chris Glantz, MD, MPH Severe Maternal Morbidity (SMM) Severe/multisystem

and Maternal Mortality Chris Glantz, MD, MPH Severe Maternal Morbidity (SMM) Severe/multisystem

Severe Maternal Morbidity and Maternal Mortality Chris Glantz, MD, MPH Severe Maternal Morbidity (SMM) Severe/multisystem organ dysfunction or need for major intervention Defined by CDC as one or more of 18 conditions 1. Acute MI/aneurysm 10.

634 views • 29 slides
Maternal Mortality and Severe Morbidity in Arizona Attached to every statistic there is a

Maternal Mortality and Severe Morbidity in Arizona Attached to every statistic there is a

Maternal Mortality and Severe Morbidity in Arizona Attached to every statistic there is a person, family, child, or community. Dr. George Askew, MD, FAAP New York City Deputy Commissioner of Health Enid Quintana Torres, MPH Martn F.

664 views • 45 slides
1 Maternal Mortality and Severe Morbidity in Arizona Attached to every statistic there is a

1 Maternal Mortality and Severe Morbidity in Arizona Attached to every statistic there is a

1 Maternal Mortality and Severe Morbidity in Arizona Attached to every statistic there is a person, family, child, or community. Dr. George Askew, MD, FAAP New York City Deputy Commissioner of Health Enid Quintana Torres, MPH Martn

731 views • 47 slides
Major Causes of Morbidity and Mortality in SLE Patient EM EM, an 18-year-old Black female

Major Causes of Morbidity and Mortality in SLE Patient EM EM, an 18-year-old Black female

Major Causes of Morbidity and Mortality in SLE Patient EM EM, an 18-year-old Black female presents to the emergency department (ED) with acute onset of confusion and hallucinations Her parents report she has been complaining of

1.1k views • 65 slides
Major Causes of Morbidity and Mortality in SLE Patient EM EM, an 18-year-old Black female

Major Causes of Morbidity and Mortality in SLE Patient EM EM, an 18-year-old Black female

Major Causes of Morbidity and Mortality in SLE Patient EM EM, an 18-year-old Black female presents to the Emergency Department with acute onset of confusion and hallucinations Her parents report that she has been complaining of

682 views • 64 slides
Gastrointestinal haemorrhage A common emergency Important cause of mortality and morbidity

Gastrointestinal haemorrhage A common emergency Important cause of mortality and morbidity

Gastrointestinal haemorrhage A common emergency Important cause of mortality and morbidity Case fatality is high (10 20% in the UK) Rockall TA et al. BMJ, 1995. 311(6999): p. 222-6. Williams JG et al. Gut, 2007. 56 Suppl 1:

734 views • 14 slides
AND DIS-EASE (MORBIDITY) IN THE NEWBORN Balaji Govindaswami, MD, MPH Chief, Newborn Medicine,

AND DIS-EASE (MORBIDITY) IN THE NEWBORN Balaji Govindaswami, MD, MPH Chief, Newborn Medicine,

COMMON CAUSES OF DEATH (MORTALITY) AND DIS-EASE (MORBIDITY) IN THE NEWBORN Balaji Govindaswami, MD, MPH Chief, Newborn Medicine, SCVMC Director NICU and High Risk Follow-Up Clinical Professor (Affiliated) of Pediatrics Neonatal &amp;

597 views • 26 slides
Pneumococcal Disease: Morbidity and Mortality 1 Streptococcus pneumoniae (Pneumococcus)

Pneumococcal Disease: Morbidity and Mortality 1 Streptococcus pneumoniae (Pneumococcus)

Access additional quality improvement strategies by visiting the full toolkit here: www.achlcqicme.org/pneumonia/toolkit.apsx Pneumococcal Disease: Morbidity and Mortality 1 Streptococcus pneumoniae (Pneumococcus) Gram-positive bacteria

737 views • 27 slides
in Yorkshire and the Humber National Service Specification Gap Analysis Dr Alexis Gilbert

in Yorkshire and the Humber National Service Specification Gap Analysis Dr Alexis Gilbert

Commissioning of TB Services in Yorkshire and the Humber National Service Specification Gap Analysis Dr Alexis Gilbert Specialty Registrar in Public Health January 2017 National Strategy Areas for action (The Collaborative Tuberculosis

622 views • 20 slides
RESULTS United National Webinar Our Anti-Oppression Values 2 RESULTS is a movement of

RESULTS United National Webinar Our Anti-Oppression Values 2 RESULTS is a movement of

RESULTS United National Webinar Our Anti-Oppression Values 2 RESULTS is a movement of passionate, committed everyday people. Together we use our voices to influence political decisions that will bring an end to poverty. Poverty cannot end as

738 views • 50 slides
The Case for Common Goods for Health Welcome to this webinar session, we will be starting soon.

The Case for Common Goods for Health Welcome to this webinar session, we will be starting soon.

Webinar session - Building the Reset Series The Case for Common Goods for Health Welcome to this webinar session, we will be starting soon. Check the chat box for links and relevant information. Featuring: Agns Jesse B. Palitha Emmanuel

334 views • 8 slides
Welcome to the HIV-TB Research Symposium MRC Clinical and

Welcome to the HIV-TB Research Symposium MRC Clinical and

Welcome to the HIV-TB Research Symposium MRC Clinical and Community HIV-TB Research Collaborating Centre Livingstone Hospital, 20 October 2017 Clinical &amp;

213 views • 7 slides
Chronic treatment with ivermectin changes drug disposition in mice through modulation of

Chronic treatment with ivermectin changes drug disposition in mice through modulation of

10th French-Belgian ABC meeting Brussels, Belgium, October 19-20, 2012 Chronic treatment with ivermectin changes drug disposition in mice through modulation of metabolism gene expression Mlanie Albrich , Ccile Mnez, Anne Lespine

263 views • 9 slides
HIV Pharmacology Parya Saberi, PharmD, MAS, AAHIVP Associate Professor, UCSF Center for AIDS

HIV Pharmacology Parya Saberi, PharmD, MAS, AAHIVP Associate Professor, UCSF Center for AIDS

12/13/19 HIV Pharmacology Parya Saberi, PharmD, MAS, AAHIVP Associate Professor, UCSF Center for AIDS Prevention Studies The Medical Management of HIV and Hepatitis December 2019 1 Disclosure I have nothing to disclose 2 P. Saberi,

568 views • 35 slides
+ The Development &amp; Science of the APRAIS Neil Websdale + APRAIS: Arizona intimate Partner

+ The Development &amp; Science of the APRAIS Neil Websdale + APRAIS: Arizona intimate Partner

Thank you for joining us today! The Science and Practice of Community Informed Risk Assessment January 25, 2018 2 3:30pm CST Neil S. Websdale, Ph.D ., Director, Family Violence Institute, NAU and Greg Giangobbe, MA , Law Enforcement Coordinator,

691 views • 24 slides
UPDATE Niraparib and niraparib-bevacizumab combination against bevacizumab alone in Women with

UPDATE Niraparib and niraparib-bevacizumab combination against bevacizumab alone in Women with

NSGO EARLY PHASE CLINICAL TRIALS UPDATE Niraparib and niraparib-bevacizumab combination against bevacizumab alone in Women with Homologous Recombination Deficient (HRD) platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer.

339 views • 15 slides

More recommend